Key result
CMV infection after allogeneic bone marrow transplantation was significantly associated with a higher mean number of natural autoantibodies (3.1 for CMV disease vs 0.9 for CMV-negative; P=0.006).
Why the study?
Does CMV infection increase the occurrence of autoantibodies and monoclonal gammopathies in allogeneic bone marrow transplant recipients?
Population
95 consecutive recipients of an allogeneic marrow transplant
Comparison
CMV infection (asymptomatic or disease) vs CMV-negative patients
Design
Cohort
Follow-up
early post-transplant
Authors
Loading...
Autoantibody monitoring may not be routinely warranted after allogeneic transplant; leaves open whether B-cell ontogeny is recapitulated in this setting.
Cohort (n=95)
Does CMV infection increase the occurrence of autoantibodies and monoclonal gammopathies in allogeneic bone marrow transplant recipients?
Absolute Event Rate: 3.1% vs 0.9%
p-value: p=0.006
CMV infection after allogeneic bone marrow transplantation is associated with a higher prevalence of natural autoantibodies and monoclonal gammopathies, suggesting nonspecific B-cell stimulation.
Hebart et al. (1996) conducted a cohort in Allogeneic marrow transplant (n=95). CMV infection vs. CMV-negative status was evaluated on Mean number of natural antibodies (p=0.006). CMV infection after allogeneic bone marrow transplantation was significantly associated with a higher mean number of natural autoantibodies (3.1 for CMV disease vs 0.9 for CMV-negative; P=0.006).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: